Cypro

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cypro

What is Cypro (Cyproheptadine)? Identity and Purpose

The medicine known as Cypro contains the active compound Cyproheptadine Hydrochloride, a synthetic therapeutic agent classified by its dual pharmacological activity. Periactin is another well-known trade name for this same formulation.

Property Description
Active ingredient Cyproheptadine Hydrochloride
Form Tablet, oral solution, or syrup
Pharmacological class First-generation Antihistamine
Common use Relief of allergic symptoms
Origin Synthetic (Piperidine derivative)

What is Cyproheptadine and How is it Classified?

Cyproheptadine is defined as a first-generation antihistamine for oral administration, belonging to the piperidine derivative family of chemical substances. This classification is supported by pharmacological studies confirming its primary function as a potent H1-receptor antagonist. The classification as a first-generation agent is a differentiating factor because it readily affects the central nervous system, leading to its characteristic sedative effects and anticholinergic properties.

The drug is further distinguished by its unique dual mechanism, acting as both a histamine antagonist and a serotonin antagonist. This additional property means the medicine is clinically recognized for its robust and comprehensive antagonistic profile against both of these key inflammatory mediators.


Available Forms and General Purpose of Cypro

This single-ingredient product is supplied in common oral dosage forms, including tablets, syrup, and oral solution. The availability of liquid forms, such as the syrup, is a key feature, allowing for more flexible dosing, particularly in patient groups who have difficulty swallowing tablets.

The general purpose of this medicine is the relief of symptoms associated with various allergic conditions. For example, it is often employed to manage the discomfort associated with itching (pruritus) or chronic hives (urticaria). By simultaneously competing for both histamine and serotonin receptors, Cyproheptadine offers a broad therapeutic approach to managing symptoms linked to these two chemical messengers.

Regulatory References

  1. National Institutes of Health - LiverTox: Cyproheptadine
  2. MedlinePlus Drug Information: Cyproheptadine

What side effects are possible with Cypro?

Possible Side Effects and Safety Information for Cyproterone Acetate

This information describes the adverse reactions and safety constraints for cyproterone acetate as documented in official government regulatory documents (e.g., FDA, EMA).

Frequency-Classified Adverse Reactions

Side effects are classified by their expected frequency, as per regulatory standards:

Classification Examples of Adverse Reactions (Not a complete list)
Very Common (Affects 1 in 10 people or more) Decreased libido, reversible inhibition of sperm production (men) or ovulation (women), tiredness, headache.
Common (Affects less than 1 in 10) Depressed mood, weight changes, breast enlargement (men), gastrointestinal complaints, hot flushes.
Rare (Affects less than 1 in 1,000) Hypersensitivity reactions.

Serious Adverse Reactions and Key Safety Concerns

Regulatory documents highlight several rare but serious safety concerns that require careful monitoring:

  • Liver Toxicity: Direct toxicity to the liver, including hepatitis, jaundice, and hepatic failure, with reports of fatal outcomes, particularly at high doses.
  • Meningioma Risk: Use of the drug, particularly at high cumulative doses over long periods, is associated with an increased risk of a specific type of benign brain tumor called meningioma. Treatment must be permanently discontinued if this is diagnosed.
  • Thromboembolic Events: Cases of blood clots (e.g., deep vein thrombosis, pulmonary embolism) have been documented.

Safety Constraints and Monitoring

Cyproterone acetate is contraindicated (should not be used) in patients with severe liver disease, liver tumors, pregnancy, or a history of meningioma. Regular liver function testing is required during treatment. Specific safety statements are documented for use in pregnancy, where the medication is forbidden, and in patients with hepatic impairment, where the existing risk of toxicity is amplified.

Overdose and Emergency Response

The official regulatory profile for a Cyproheptadine overdose details acute toxicity affecting the Central Nervous System (CNS) and the cardiovascular and respiratory systems. All instances of suspected overdosage require immediate medical attention.

Documented Manifestations

Overdose manifestations include a spectrum of CNS effects, ranging from profound drowsiness, confusion, and lethargy to signs of stimulation such as agitation, hallucinations, tremor, and convulsions. Anticholinergic signs, commonly described as atropine-like, are also documented, presenting as fever, dry mouth, dilated pupils, and urinary retention.

Severe Outcomes and Risk

Due to the drug's toxicity, severe overdosage may lead to life-threatening outcomes including cardiac arrest and respiratory arrest. The regulatory documentation notes that overdosage is particularly severe and potentially fatal in infants and young children. The elderly are also cited as being more susceptible to adverse CNS effects and urinary retention.

Emergency Action Required

Immediate medical attention must be sought, or a poison control center must be contacted, especially if the individual exhibits severe symptoms such as seizures, trouble breathing, or loss of consciousness. As no specific antidote is known, regulatory guidance states that management involves immediate symptomatic and supportive treatment, with measures such as gastric lavage and administration of activated charcoal described as possible procedural steps.

Therapeutic Uses of Cypro

What Cypro Treats: Main Uses and Benefits

The medicine Cyproheptadine is used for managing symptoms related to physical discomfort and systemic imbalance, focusing on easing the overall symptom load associated with heightened physiological responses and specific neurological patterns. It is commonly used in conditions presenting with systemic or localized discomfort.

Managing Severe Itching and Allergic Manifestations

This domain is commonly used to help with managing symptoms that interfere with daily comfort from allergic rhinitis, hives (urticaria), and severe itching (pruritus). It is applied in contexts where symptoms related to inflammatory or irritative states are creating noticeable interference with daily stability. The benefit is relevant for easing discomfort and contributes to improved comfort during periods of heightened symptoms.

Supportive Use for Appetite Loss and Recurrent Headaches

Cypro is applied in addressing the symptom of poor appetite (anorexia), a condition where functional stability becomes affected. It is commonly used to help with managing symptoms related to this nutritional strain. Additionally, it may assist with managing symptom clusters that may become intense or disruptive in the prophylactic management of recurrent vascular headaches like migraines.


Quick Fact: Relief for Itching and Headaches
Cypro is commonly used across domains where additional symptomatic support is needed, providing support that helps ease the overall symptom burden of persistent itching and recurrent vascular headache manifestations.

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Cyproheptadine — Official Regulatory Information

Eligibility Scope

Populations for whom use is allowed (as stated in label):

  • Children ge 2 years of age and adults (subject to contraindications).

Populations for whom use is contraindicated:

  • Newborn or premature infants, nursing mothers, and debilitated geriatric patients.

Age-Related Eligibility Rules

  • Infants/Neonates: Use is absolutely contraindicated.
  • Children under 2 years: Safety and effectiveness have not been established.
  • Older Adults: Use requires caution due to an increased risk of side effects.

Condition-Specific Eligibility Rules

  • Absolute Contraindications: The medicine is prohibited in patients with angle-closure glaucoma, stenosing peptic ulcer, pyloroduodenal obstruction, or symptomatic prostatic hypertrophy. Use is also forbidden in patients concurrently receiving Monoamine Oxidase (MAO) Inhibitor Therapy.
  • Conditional Use: The medicine should be used with caution in patients with a history of bronchial asthma, increased intraocular pressure, hyperthyroidism, cardiovascular disease, or hypertension. Elimination may also be diminished in cases of renal insufficiency.

Pregnancy and Lactation Eligibility Status

  • Pregnancy: Classified as FDA Pregnancy Category B, meaning use is permitted only if clearly needed.
  • Lactation: Use is contraindicated due to the potential for adverse effects in nursing infants.

Connection to the Overall Eligibility Profile

The regulatory profile defines non-eligibility through absolute contraindications for high-risk populations, including all infants and nursing mothers. Furthermore, the label requires the medicine to be avoided in patients with specific gastrointestinal or urinary obstructions due to its inherent pharmacological action, thereby limiting use to populations without these specific exclusion factors.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Formal Regulatory Restrictions and Contraindications

The interaction profile for Cyproheptadine is established by specific pharmacodynamic properties, resulting in formal restrictions and prohibitions documented in regulatory labeling. Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is contraindicated. This restriction is documented because MAO inhibitors are known to prolong and intensify the anticholinergic effects of Cyproheptadine. Use is also officially contraindicated in specific populations due to intensified interaction risk, including the elderly, debilitated patients, newborns, premature infants, and nursing mothers.


Pharmacodynamic Effects and Cautions

Regulatory information states that Cyproheptadine may have additive CNS depressant effects when used alongside other CNS Depressants, such as sedatives, hypnotics, and tranquilizers. Similarly, concurrent use with alcohol is documented as resulting in additive effects, increasing the risk of dizziness and drowsiness.

Cyproheptadine possesses anti-serotonin activity, which is documented to interfere with the intended effects of serotonin-enhancing antidepressants (e.g., SSRIs), potentially leading to a recurrence of symptoms. Furthermore, it is documented that Cyproheptadine may cause a false positive test result for Tricyclic Antidepressant (TCA) drugs during diagnostic drug screening. No specific CYP enzyme or transporter-mediated interactions are explicitly documented at a high, label-defined level.

Mechanism of Action

Primary Action: Histamine H1 Receptor Blockade

This mechanism involves Cyproheptadine acting as a competitive antagonist at the Histamine H1 receptors throughout the body. By binding to these receptors, it interrupts the signaling of histamine, a key inflammatory mediator, and modifies downstream physiological responses resulting from histamine-mediated signaling.


Secondary Action: Serotonin 5-HT2 Receptor Modulation

Cyproheptadine also engages mechanisms by acting as an antagonist at specific Serotonin 5-HT2 receptors in the central nervous system and peripheral tissues. This targeted pathway adjustment influences signaling within pathways that include regulation of energy balance and serotonergic activity.


Ancillary Effect: Muscarinic Acetylcholine Receptor Antagonism

This drug engages an ancillary mechanistic domain by showing affinity for and blocking Muscarinic Acetylcholine Receptors. This interaction with the cholinergic system alters activity within the cholinergic system, resulting in physiological consequences characteristic of muscarinic receptor antagonism.

Dosage and Administration Information

How Cyproheptadine is Used: Official Administration Guidelines

Cyproheptadine is an oral-only medication, available in tablets (typically 4 mg strength) or as an oral solution/syrup (2 mg per 5 mL). The administration protocol is defined by divided dosing and highly individualized adjustment, strictly adhering to maximum limits.


Standard Dosage and Frequency

For adults, the typical starting dose is 4 mg three times a day (t.i.d.). The daily dose is usually administered in divided portions because the effect of a single dose lasts approximately four to six hours. While a majority of adults require between 12 mg and 16 mg per day, the official limit for the total daily dose is 32 mg per day or 0.5 mg/kg/day, whichever is lower.

In relation to food, the medicine is generally taken without regard to meals; however, it may be taken with food for certain uses.

Population-Specific Use and Preparation

Official guidelines require specific dose adjustments for certain age groups. For older adults, dosing should begin at the low end of the usual range. Pediatric dosing is based on age and weight, with a maximum of 16 mg a day for children aged 7–14 and 12 mg a day for children aged 2–6.

If the oral solution is used, it must be measured with a calibrated dosing device to ensure accurate intake, as household spoons are not considered reliable for precise medication measurement.

Handling Missed Doses

If a scheduled dose is missed, instructions advise taking it as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped, and the regular schedule resumed. The dose should never be doubled to compensate for a missed administration.

Recent Clinical Evidence

Research evidence / Overview of studies for Cyproheptadine

Evidence for Use in Research Exploring Allergic Symptoms and Chronic Urticaria

The clinical evaluation for Cyproheptadine in research exploring allergic conditions, such as chronic urticaria (hives) and allergic rhinitis, has primarily relied on Randomized Controlled Trials (RCTs) and comparative studies. This research was used in research exploring how symptoms change over time. Studies monitored outcomes linked to inflammatory or irritative states, such as changes in symptom severity scores and measurements of the overall impact on daily functioning or activity level.

The trials included populations of adults with persistent allergic manifestations, often focusing on patients whose symptoms remained challenging to manage despite using maximum doses of newer-generation antihistamines. Research highlights changes measured during the study period in these groups, with findings describing patterns in the patient-reported outcomes describing perceived discomfort. Because the medicine has been in use for many years, a significant portion of the foundational evidence is historical in nature.

Studies on Poor Appetite and Nutritional Status

Cyproheptadine was studied for the management of poor appetite (anorexia) and its evaluation in research focused on weight change, particularly in pediatric populations. The research available includes Randomized Controlled Trials (RCTs) and systematic reviews. Research examined outcomes related to systemic or functional imbalance, such as changes in body weight and standardized metrics of growth (like BMI Z-scores in children).

Findings describe patterns observed in the studies over time, with reported outcomes tracking changes in measured weight and height, generally over mid-term periods of two to six months. Evidence contributes to understanding symptom patterns related to poor appetite. However, sample sizes were modest in some key studies, and comparative evidence is lacking for many direct head-to-head comparisons against newer agents.

Research in Scenarios Related to Recurrent Headaches

The evidence base exploring Cyproheptadine in research scenarios related to reducing the frequency of recurrent headaches, such as migraines, mainly consists of a collection of small clinical trials, open-label studies, and retrospective reviews. The research monitored outcomes describing episodic or acute changes, focusing on measurements such as the frequency of headaches per month and the change in their reported duration or intensity.

The weight of the evidence surrounding this research is generally categorized as low. This is due to a significant lack of large, methodologically robust RCTs necessary to confirm findings broadly. Follow-up durations were limited, generally extending only three to six months.

Research Gaps and Areas of Uncertainty

Long-term effects are not fully established for most indications, as follow-up durations are often short. Data for certain groups remain insufficient, including evidence specific to older adults, and data remain scarce in the authorized sources regarding its study during pregnancy or breastfeeding. Results apply only to the populations studied and cannot be assumed for groups where research has not been conducted or reported.

Key Studies & References

  1. CYPROHEPTADINE HYDROCHLORIDE TABLETS USPRx only (Official FDA Drug Label and Indications)
  2. Role of cyproheptadine in chronic urticaria not controlled with second-generation antihistamines: a retrospective study
  3. Preventive Therapy in Pediatric Migraine (Clinical Guideline Resource)

Frequently Asked Questions (FAQ)

Common questions about Cypro (FAQ)

Q: How quickly should I expect to feel better after starting Cypro?

A: Regulatory documents do not provide a specific timeframe for when the medication should start working. However, official product information describes some common side effects, such as drowsiness, as transient (short-lived), which suggests the drug’s effects can begin relatively quickly, although the therapeutic response time is not explicitly stated.

Q: What is the typical length of time a person takes Cypro for a standard infection?

A: Cyproheptadine is a first-generation antihistamine primarily indicated for the treatment of allergic conditions like chronic hives, not for treating infections. Because of this, there is no official 'typical length of time' for its use against an infection. The duration of therapy is highly individualized and depends on the specific allergic symptoms being managed.

Q: Is it normal to still have some symptoms after a few days on Cypro?

A: Official documents focus on the drug's intended action as an antihistamine and its reported side effects, rather than providing expectations for symptom clearance. If symptoms persist, worsen, or change unexpectedly after starting the medication, consulting a healthcare provider is generally recommended.

Q: Is diarrhea a frequent side effect of Cypro, and how long does it usually last?

A: Diarrhea is listed as a reported gastrointestinal side effect of Cyproheptadine, generally falling under the category of commonly observed digestive system adverse reactions. While its frequency is noted, the exact duration of diarrhea or other digestive issues is not specified in the official regulatory labeling.

Q: Does Cypro cause an upset stomach or nausea, and can taking it with food help?

A: Nausea, vomiting, and epigastric distress (stomach upset) are reported as possible side effects. Official administration guidelines state that while the medication is often taken without regard to meals, it is permitted to take it with food. Taking the medication with food is a general strategy often utilized when stomach upset occurs.

Q: Is it safe to drink milk or eat dairy products while on Cypro?

A: The official administration guidance states that Cyproheptadine may generally be taken without regard to meals. There are no specific instructions or warnings provided in the regulatory labeling to avoid milk or other dairy products while taking this medication.

Q: Is Cypro safe for use in children for common infections?

A: Cyproheptadine is not approved for the treatment of infections; its authorized use in children aged 2 years and older is for allergic conditions. The safety and effectiveness of the medication are established only for these specific authorized allergic indications.

Q: What research is currently being done on the long-term safety of Cypro?

A: Official documents indicate that long-term effects of Cyproheptadine are not fully established, as follow-up durations in key studies have often been short. Furthermore, long-term studies to assess the potential for carcinogenic effects have not been conducted. Information on current ongoing research trials is not typically detailed within the official drug label itself.

Q: Is there a way to lessen the severity of the common gastrointestinal side effects?

A: The official administration guidelines note that while the drug is typically taken without reference to meals, it is permissible to take the medicine with food for certain uses. Taking the medication with food is a general strategy often considered for managing common gastrointestinal side effects.

Q: Are there any known long-term effects associated with Cypro use?

A: Official regulatory information states that the long-term effects of Cyproheptadine are not fully established because the follow-up periods in many foundational studies were limited. In addition, regulatory documents confirm that long-term studies to assess carcinogenic potential have not been conducted.

Q: What are the serious, but less common, side effects of Cypro I should be aware of?

A: Reported serious but less common adverse reactions include, but are not limited to, changes in blood cell counts (such as leukopenia or agranulocytosis), convulsions (seizures), and anaphylactic shock (a severe allergic reaction). Cardiovascular effects like hypotension and tachycardia have also been reported.

Q: Are there risks of tendon problems or tendon rupture linked to Cypro use?

A: Official safety information for Cyproheptadine does not list tendon problems or tendon rupture as documented adverse reactions in its regulatory labeling.

Q: Can Cypro cause numbness, tingling, or pain in the arms or legs (peripheral neuropathy)?

A: Official reports of central nervous system side effects have included paresthesia and neuritis. Paresthesia is a sensation of numbness, tingling, or prickling. Neuritis refers to the inflammation of a nerve.

Q: How can Cypro affect mood, anxiety, or sleep patterns?

A: The official labeling reports several central nervous system side effects that can affect these areas. These include sedation, sleepiness (often temporary), dizziness, restlessness, excitement, nervousness, irritability, and insomnia (difficulty sleeping).

Q: Does Cypro increase sensitivity to sun exposure or cause a severe sunburn?

A: Yes, official safety information lists photosensitivity as a reported integumentary (skin-related) adverse reaction. Photosensitivity means an increased sensitivity of the skin to sunlight.

Q: Is there a risk of an abnormal heart rhythm or 'long QT syndrome' with Cypro?

A: Reported cardiovascular adverse reactions include palpitation (a noticeable strong or irregular heartbeat), tachycardia (a fast heartbeat), and extrasystoles (extra or premature heartbeats). While these are reported, the regulatory labeling does not specifically use the term 'long QT syndrome'.

Q: Is it true that Cypro can be used for anthrax exposure prevention?

A: Cyproheptadine is an antihistamine indicated for the relief of allergic symptoms. The official regulatory label does not list anthrax exposure prevention as an approved or authorized use for this medication.

Q: What are the specific concerns for people with a history of seizures taking Cypro?

A: Official product information reports that convulsions (seizures) have occurred as a Central Nervous System adverse reaction. Cautionary statements are noted for populations with a history of seizures or epilepsy, given this documented risk.

Q: Why are there warnings about central nervous system (CNS) effects with Cypro?

A: Warnings are in place due to the drug's inherent Central Nervous System depressant effects, such as causing drowsiness. Furthermore, there is a risk of additive CNS depression if the drug is taken concurrently with other substances that slow brain activity, such as alcohol, sedatives, or tranquilizers.

Q: Can Cypro be used as ear or eye drops, or only as an oral medication?

A: Cyproheptadine is currently approved for use only as an oral medication. It is supplied in dosage forms such as tablets and oral solution or syrup. Other forms, such as ear or eye drops, are not authorized dosage forms listed in official regulatory documents.

Q: Does Cypro interact with antidepressants or other psychiatric medications?

A: Yes, regulatory documents note that Cyproheptadine's action as an anti-serotonin agent can interfere with the intended effects of serotonin-enhancing antidepressants. Additionally, it can cause additive CNS depressant effects when used with other CNS-active medications like tranquilizers and sedatives.

Q: Is it normal to have a slight headache or dizziness while on Cypro?

A: Yes, headache is listed as a very common side effect in official reports. Dizziness is also listed as a commonly reported adverse reaction under the drug's Central Nervous System effects.

Q: Why is Cypro sometimes prescribed for complicated abdominal infections?

A: Cyproheptadine is an antihistamine used for allergic conditions. The regulatory label does not list abdominal infections as an approved indication or use. Any use for conditions outside of its approved allergic indications is not covered by the official product information.

How should Cypro be stored and disposed of?

The storage and disposal of Cyproheptadine (Cypro) must strictly adhere to regulatory labeling to maintain product stability and ensure household safety.

Official Storage and Disposal Requirements

The medicine requires storage at controlled room temperature, specifically 20°C to 25°C (68°F to 77°F), with brief deviations permitted up to 30°C. The container must be kept tightly closed in its original packaging to ensure protection from both light and moisture. For household safety, the medicine must be stored out of the reach and sight of children.

Disposal of unused or expired product must be managed according to local regulations. Authorities recommend utilizing drug take-back programs when available. If a take-back program is not accessible, the product should be mixed with an undesirable substance (e.g., dirt or coffee grounds) and sealed in a container before being placed in the household trash, following the specific procedure authorized by the FDA.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cypro found in:

A-Z Index: